Terry Heiman-Patterson, MD, Professor of Neurology at the Lewis Katz School of Medicine at Temple University, spoke with PhillyVoice about the results of the phase 2 trial for AMX0035, a treatment for amyotrophic lateral sclerosis (ALS) that combines two existing drugs, sodium phenylbutyrate and tauroursodeoxycholic acid, to target two different facets of the disease’s progression. Dr. Heiman-Patterson was the principal investigator at Temple.
Our locations are open for appointments and procedures. See how we're providing safe in-person care and telemedicine visits.
(Nuestras facilidades están abiertas para citas y procedimientos. Vea cómo brindamos atención segura en persona y visitas por medio de telemedicina.)
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH